Search
Tapinarof
go.drugbank.com/drugs/DB06083ApprovedInvestigationalIt is available as a topical cream to be applied to the affected area once daily. … [A248790] Tapinarof received initial approval from the FDA in 2022.[L41845]
Vaborbactam
go.drugbank.com/drugs/DB12107ApprovedInvestigationalVaborbactam is added to the therapy to reduce the extent meropenem degradation by inhibiting the serine beta-lactamases expressed by the microorganism of target. … [Label] The treatment aims to resolve infection-related symptoms of cUTI and achieve negative urine culture, when the infections are proven or strongly suspected to be caused by susceptible bacteria.
Technetium Tc-99m red blood cells
go.drugbank.com/drugs/DB09493ApprovedWithdrawnAutologous red blood cells are radiolabeled with sodium pertechnetate Tc 99m in the reaction vial. … It is suggested that _in vitro_ labelling improves the heart-to-background ratio during imaging [A32181].
Synonyms: Technetium Tc 99m red blood cells, Technetium Tc-99m red blood cellVonoprazan
go.drugbank.com/drugs/DB11739ApprovedInvestigational[A253702] Furthermore, vonoprazan is 350-times more potent than the proton-pump inhibitor [lansoprazole], thanks to its ability to accumulate in the gastric corpus mucosa, specifically in the parietal … PCABs represent an alternative to proton-pump inhibitors for the treatment of acid-related disorders.
Etryptamine
go.drugbank.com/drugs/DB01546ApprovedIllicitWithdrawnIn the 1960's, alpha-ethyltryptamine (αET), a non hydrazine reversible monoamine oxidase inhibitor, was developed in the United States by the Upjohn chemical company for use as an antidepressant. αET was … However, in 1962, after the discovery of an unacceptable incidence of agranulocytosis, the development of Monase was halted and the drug was withdrawn from potential market use.
Bivalirudin
go.drugbank.com/drugs/DB00006ApprovedInvestigationalOnce bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously. … Because it can cause blood stagnation, it is important to monitor changes in hematocrit, activated partial thromboplastin time, international normalized ratio and blood pressure.
Products: BIVACARD 250 MG IV ENJEKSIYON VE INFÜZYON IÇIN LIYOFILIZE TOZ IÇEREN FLAKON, 1 ADETPlant-based virus-like particles, recombinant, adjuvanted COVID-19 vaccine
go.drugbank.com/drugs/DB16757Approvedfor the prevention of COVID-19. … (e.g. the [AstraZeneca COVID-19 vaccine]) and nucleic acid vaccines (e.g. the [Moderna COVID-19 vaccine]).
Tiludronic acid
go.drugbank.com/drugs/DB01133ApprovedVet approvedWithdrawn[A1923,A203111] These drugs were developed to mimic the action of pyrophosphate, a regulator of calcification and decalcification. … Tiludronate, or (4-chlorophenyl)thio-methylene-1,1-bisphosphonate, is a first generation bisphosphonate similar to [etidronic acid] and [clodronic acid].
Roxithromycin
go.drugbank.com/drugs/DB00778ApprovedInvestigationalWithdrawnIt was shown to be more effective against certain Gram-negative bacteria, particularly _Legionella pneumophila_. … Roxithromycin exerts its antibacterial action by binding to the bacterial ribosome and interfering with bacterial protein synthesis.
Synonyms: (9E)-erythromycin 9-(O-((2-methoxyethoxy)methyl)oxime)International brands: Heng Te, Bei KeSecukinumab
go.drugbank.com/drugs/DB09029ApprovedInvestigational[L39600] By blocking the actions of IL-17A, secukinumab works to inhibit the pro-inflammatory pathways that drive immune-mediated inflammatory disorders. … [A249840] Following its first global approval in Japan in December 2014, secukinumab was approved by the European Commission on January 15, 2015, and by the FDA a few days after (January 21, 2015).